Boehringer Ingelheim's Lung Cancer Drug Hernexeos Gains FDA Approval
The US FDA has approved Boehringer Ingelheim's drug Hernexeos for treating advanced non-squamous non-small cell lung cancer in patients who have previously received treatment, based on a study showing significant tumor reduction, with an accompanying diagnostic device approval for patient identification.